浏览全部资源
扫码关注微信
1.湖北中医药大学 药学院,武汉 430065
2.湖北中医药大学 中药资源与中药复方教育部重点实验室,武汉 430065
Received:27 February 2022,
Published Online:22 June 2022,
Published:20 August 2022
移动端阅览
李励,邓冬杰,谈相云等.葫芦素B调控糖酵解抑制HuCCT1细胞增殖的作用机制[J].中国实验方剂学杂志,2022,28(16):74-81.
LI Li,DENG Dongjie,TAN Xiangyun,et al.Mechanism of Cucurbitacin B in Regulating Glycolysis and Inhibiting Proliferation of HuCCT1 Cells[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(16):74-81.
李励,邓冬杰,谈相云等.葫芦素B调控糖酵解抑制HuCCT1细胞增殖的作用机制[J].中国实验方剂学杂志,2022,28(16):74-81. DOI: 10.13422/j.cnki.syfjx.20221624.
LI Li,DENG Dongjie,TAN Xiangyun,et al.Mechanism of Cucurbitacin B in Regulating Glycolysis and Inhibiting Proliferation of HuCCT1 Cells[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(16):74-81. DOI: 10.13422/j.cnki.syfjx.20221624.
目的
2
探究葫芦素B(CuB)抑制细胞增殖和糖酵解的作用机制。
方法
2
采用细胞增殖与活性检测-8(CCK-8)法检测CuB(0、40、80、120、160、200、400、800 nmol·L
-1
)对HuCCT1细胞增殖的影响;采用平板克隆实验检测CuB(50、100、200 nmol·L
-1
)对HuCCT1细胞集落形成能力的影响;采用流式细胞术检测CuB(50、100、200 nmol·L
-1
)对HuCCT1细胞周期的影响;采用可见分光光度法检测CuB(50、100、200 nmol·L
-1
)给药后HuCCT1细胞中糖酵解关键酶己糖激酶(HK)、丙酮酸激酶(PK)活性,及葡萄糖消耗量、乳酸生成量和三磷酸腺苷(ATP)生成量的变化;采用蛋白免疫印迹法(Western blot)检测CuB对细胞周期相关蛋白、增殖相关蛋白、糖酵解关键蛋白及蛋白激酶B/哺乳动物雷帕霉素靶蛋白(Akt/mTOR)通路相关蛋白表达情况的影响。
结果
2
与空白组比较,给药24 h,160~800 nmol·L
-1
CuB,给药48 h后80~800 nmol·L
-1
可以抑制HuCCT1细胞增殖(
P
<
0.05
, P
<
0.01),并呈时间和浓度依赖性,给药48 h半数抑制浓度为200 nmol·L
-1
; CuB可以呈浓度依赖性的抑制HuCCT1细胞集落形成能力(
P
<
0.01);CuB能够将HuCCT1细胞周期阻滞在G
2
期(
P
<
0.05
, P
<
0.01);CuB(100、200 nmol·L
-1
)可以抑制糖酵解关键酶HK、PK的活性,并降低细胞葡萄糖消耗量及乳酸和ATP的生成量(
P
<
0.05,
P
<
0.01)。Western blot结果显示,CuB(100、200 nmol·L
-1
)可以抑制周期相关蛋白Cyclin B
1
、增殖细胞核抗原(PCNA)、己糖激酶1(HK1)、己糖激酶2(HK2)、丙酮酸激酶1(PKM1)、丙酮酸激酶2(PKM2)、磷酸化蛋白激酶B(p-Akt)、磷酸化mTOR(p-mTOR)及磷酸化核糖体蛋白(p-RPS6)的蛋白表达水平(
P
<
0.05
, P
<
0.01)。
结论
2
CuB可能通过调控Akt/mTOR通路抑制HuCCT1细胞糖酵解进而影响细胞增殖。
Objective
2
To explore the mechanism of cucurbitacin B (CuB) in inhibiting cell proliferation and glycolysis.
Method
2
Cell counting kit-8 (CCK-8) was applied to investigate the effect of different concentrations of CuB (0, 40, 80, 120, 160, 200, 400, and 800 nmol·L
-1
) on the proliferation of HuCCT1 cells. The effect of different concentrations of CuB (50, 100, and 200 nmol·L
-1
) on the colony formation ability of HuCCT1 cells was detected by plate cloning assay. The effect of different concentrations of CuB (50, 100, 200 nmol·L
-1
) on the HuCCT1 cell cycle was analyzed by flow cytometry. Visible spectrophotometry was employed to detect the activity of key glycolytic enzymes hexokinase (HK) and pyruvate kinase (PK)) and changes in glucose consumption, lactate production, and adenosine triphosphate (ATP) production in HuCCT1 cells after administration of different concentrations of CuB (50, 100, 200 nmol·L
-1
). Western blotting was used to assay the effect of CuB on the expression of cell cycle-related proteins, proliferation-related proteins, key glycolytic proteins, and Akt/mammalian target of rapamycin (mTOR) pathway-related proteins.
Result
2
As compared with the blank group, CuB at dose of 160-800 nmol·L
-1
after 24 h administration and CuB at dose of 80-800 nmol·L
-1
after 48 h administration inhibited the proliferation of HuCCT1 cells in a time- and dose-dependent manner (
P
<
0.05
, P
<
0.01), and the median inhibitory concentration was 200 nmol·L
-1
48 h after administration. CuB can restrain the colony formation ability of HuCCT1 cells in a dose-dependent manner (
P
<
0.01), and block HuCCT1 cell cycle in G
2
phase (
P
<
0.05
, P
<
0.01). CuB (100 and 200 nmol·L
-1
) can suppress the activities of HK and PK and reduce cell glucose consumption and production of lactate and ATP (
P
<
0.05
, P
<
0.01). Western blot results showed that CuB (100 and 200 nmol·L
-1
) can inhibit the protein levels of cycle-related protein Cyclin B
1
, proliferating cell nuclear antigen (PCNA), HK1, HK2, PKM1, PKM2, phosphorylated Akt (p-Akt), phosphorylated mTOR (p-mTOR), and phosphorylated ribosomal protein S6 (p-RPS6) (
P
<
0.05
, P
<
0.01).
Conclusion
2
CuB can inhibit aerobic glycolysis in HuCCT1 cells via the Akt/mTOR pathway, thereby affecting cell proliferation.
BLECHACZ B , KOMUTA M , ROSKAMS T , et al . Clinical diagnosis and staging of cholangiocarcinoma [J]. Nat Rev Gastro Hepat , 2011 , 8 ( 9 ): 512 - 522 .
王葵 , 沈锋 . 肝内胆管癌的诊治进展 [J]. 肝胆外科杂志 , 2019 , 27 ( 1 ): 1 - 6 .
PATEL T . Worldwide trends in mortality from biliary tract malignancies [J]. BMC Cancer , 2002 , 2 ( 1 ): 1 - 5 .
HANAHAN D , WEINBERG R A . Hallmarks of cancer: The next generation [J]. Cell , 2011 , 144 ( 5 ): 646 - 674 .
WARBURG O , WIND F , NEGELEIN E . The metabolism of tumors in the body [J]. J Gen Physiol , 1927 , 8 ( 6 ): 519 - 530 .
魏妙艳 , 汤朝晖 , 全志伟 . 代谢在肝内胆管癌发病机制及临床诊治中的研究进展 [J]. 世界华人消化杂志 , 2017 , 25 ( 33 ): 2929 - 2937 .
LUU M , PAUTZ S , KOHL V , et al . The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes [J]. Nat Commun , 2019 , 10 ( 1 ): 1 - 12 .
ZHU W , LI Y , ZHAO D , et al . Dihydroartemisinin suppresses glycolysis of LNCaP cells by inhibiting PI3K/Akt pathway and downregulating HIF-1alpha expression [J]. Life Sci , 2019 , doi: 10.1016/j.lfs.2019.116730 http://dx.doi.org/10.1016/j.lfs.2019.116730 .
DENG X , ZHAO J , QU L , et al . Ginsenoside Rh 4 suppresses aerobic glycolysis and the expression of PD-L1 via targeting Akt in esophageal cancer [J]. Biochem Pharmacol , 2020 , doi: 10.1016/j.bcp.2020.114038 http://dx.doi.org/10.1016/j.bcp.2020.114038 .
WU H , ZHAO H , CHEN L . Deoxyshikonin inhibits viability and glycolysis by suppressing the Akt/mTOR pathway in acute myeloid leukemia cells [J]. Front Oncol , 2020 , doi: 10.3389/fonc.2020.01253 http://dx.doi.org/10.3389/fonc.2020.01253 .
UENO M , KARIYA R , SITTITHUMCHAREE G , et al . Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization [J]. Phytomedicine , 2021 , doi: 10.1016/j.phymed.2021.153545 http://dx.doi.org/10.1016/j.phymed.2021.153545 .
徐菲 , 曾杨丽 , 李娟 , 等 . 中药复方防治肝癌作用机制研究进展 [J]. 中国实验方剂学杂志 , 2019 , 25 ( 24 ): 196 - 204 .
LIU P , XIANG Y , LIU X , et al . Cucurbitacin B induces the lysosomal degradation of EGFR and suppresses the CIP2A/PP2A/Akt signaling axis in gefitinib-resistant non-small cell lung cancer [J]. Molecules , 2019 , 24 ( 3 ): 647 .
XUE Y , LI R , FANG P , et al . NLRP3 inflammasome inhibitor cucurbitacin B suppresses gout arthritis in mice [J]. J Mol Endocrinol , 2021 , 67 ( 2 ): 27 - 40 .
ZHOU J , ZHAO T , MA L , et al . Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling [J]. Oncotarget , 2017 , 8 ( 61 ): 103167 - 103181 .
MARTINEZ-REYES I , CHANDEL N S . Cancer metabolism: Looking forward [J]. Nat Rev Cancer , 2021 , 21 ( 10 ): 669 - 680 .
THONSRI U , SEUBWAI W , WARAASAWAPATI S , et al . Overexpression of lactate dehydrogenase A in cholangiocarcinoma is correlated with poor prognosis [J]. Histol Histopathol , 2017 , 32 ( 5 ): 503 - 510 .
GONG X , TANG H , YANG K . PER1 suppresses glycolysis and cell proliferation in oral squamous cell carcinoma via the PER1/RACK1/PI3K signaling complex [J]. Cell Death Dis , 2021 , 12 ( 3 ): 276 .
MARCUCCI F , RUMIO C . Glycolysis-induced drug resistance in tumors-A response to danger signals? [J]. Neoplasia , 2021 , 23 ( 2 ): 234 - 245 .
严家文 , 钟俊 , 王国成 , 等 . 靶向肿瘤糖酵解途径用于肿瘤治疗的研究进展 [J]. 中国新药杂志 , 2014 , 23 ( 5 ): 550 - 556 .
LEE J D , YANG W I , PARK Y N , et al . Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake [J]. J Nucl Med , 2005 , 46 ( 10 ): 1753 - 1759 .
ZHENG M , WU C , YANG K , et al . Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis [J]. Pharmacol Res , 2021 , doi: 10.1016/j.phrs.2020.105367 http://dx.doi.org/10.1016/j.phrs.2020.105367 .
QIAO H , HE X , ZHANG Q , et al . Alpha-synuclein induces microglial migration via PKM2-dependent glycolysis [J]. Int J Biol Macromol , 2019 , doi: 10.1016/j.ijbiomac.2019.02.02 http://dx.doi.org/10.1016/j.ijbiomac.2019.02.02 .
QIAN Z , HU W , LV Z , et al . PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinoma [J]. Clin Res Hepatol Gas , 2020 , 44 ( 2 ): 162 - 173 .
JIA L , HUANG S , YIN X , et al . Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt/mTOR pathway mediated autophagy induction [J]. Life Sci , 2018 , doi: 10.1016/j.lfs.2018.07.027 http://dx.doi.org/10.1016/j.lfs.2018.07.027 .
CHEN M , ZHU Z , LV Y , et al . Effects and possible mechanism of inhibition of PI3K/Akt/mTOR signaling pathway on glycolysis of gastric adenocarcinoma cell lines [J]. Gastroenterology , 2014 , 146 ( 5 ): S328 - S329 .
ZHANG S , SONG X , CAO D , et al . Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice [J]. J Hepatol , 2017 , 67 ( 6 ): 1194 - 1203 .
HUANG J , GAO W , LIU H , et al . Up-regulated ANP32E promotes the thyroid carcinoma cell proliferation and migration via activating Akt/mTOR/HK2-mediated glycolysis [J]. Gene , 2020 , doi: 10.1016/j.gene.2020.144681 http://dx.doi.org/10.1016/j.gene.2020.144681 .
LIU G , BI Y , SHEN B , et al . SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1alpha-dependent glycolysis [J]. Cancer Res , 2014 , 74 ( 3 ): 727 - 737 .
SHI L Z , WANG R , HUANG G , et al . HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells [J]. J Exp Med , 2011 , 208 ( 7 ): 1367 - 1376 .
DANG E V , BARBI J , YANG H Y , et al . Control of T H 17/T reg balance by hypoxia-inducible factor 1 [J]. Cell , 2011 , 146 ( 5 ): 772 - 784 .
CORZO C A , CONDAMINE T , LU L , et al . HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment [J]. J Exp Med , 2010 , 207 ( 11 ): 2439 - 2453 .
LUO J , SUN P , ZHANG X , et al . Canagliflozin modulates hypoxia-induced metastasis, angiogenesis and glycolysis by decreasing HIF-1alpha protein synthesis via Akt/mTOR pathway [J]. Int J Mol Sci , 2021 , 22 ( 24 ): 13336 .
0
Views
24
下载量
3
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution